DaVita Inc. (DVA) Earnings Call Transcript & Summary
October 29, 2024
Earnings Call Speaker Segments
Nic Eliason
executiveThanks for joining us for the third quarter conference call, and we're glad you continue to take an interest in our company. This is Nic Eliason, and I serve as Group Vice President of Investor Relations. With me on the call are our CEO, Javier Rodriguez, and our CFO, Joel Ackerman. Be aware that we might make forward-looking statements on this call as that term is defined under the federal securities laws. Known and unknown risks and uncertainties apply to all such statements, and those factors could lead to actual results differing materially from what the forward-looking statements describe. For more information about those risks and uncertainties, please see our third quarter earnings press release along with our SEC filings, which include our latest annual report on Form 10-K, every subsequent quarterly report on Form 10-Q, and the other filings we subsequently make with the SEC. The information currently available to us forms the basis for our forward-looking statements, and we have no intention and take on no obligation to update them, except where the law requires it. We also want to remind you that some non-GAAP financial measures will be discussed on this call. You can find a reconciliation of those non-GAAP measures to the most comparable GAAP financial measures in our earnings press release furnished to the SEC and posted on our website. I'll hand the call over to Javier Rodriguez now.
Javier Rodriguez
executiveThanks, Nic, and I appreciate everyone being on the call today. Our frontline caregivers have my deep gratitude for their tremendous efforts, delivering excellent care to patients while also dealing with recent hurricanes and the supply interruptions that followed. Even with those difficulties, we keep pushing forward on operating efficiencies and bringing innovation across the continuum of care. Today I'll go over our third quarter results, which came in as we expected, give you an update on the supply chain, share our thinking about the upcoming CMS 2025 final rule, and close with a few remarks regarding next year; but as always, we'll begin with a clinical highlight. This quarter, we'll take the chance to shine a light on the extraordinary resilience our patients and teammates have shown when faced with the recent storms. During the last month, millions of people had their lives upended by the destruction from Hurricanes Helene and Milton. Even though hundreds of centers sat in the path of these storms, most reopened within days after the storm eased, and today every one except a single center is fully operational, delivering care in those communities. A great many inspiring stories have come out of the dialysis community, which banded together to help people in need. Right after these storms hit, our care teams from around the country mobilized to assist the affected regions. DaVita sent generators, water tankers, more than 20,000 gallons of fuel, and high-water crews to perform wellness checks and look for patients and teammates who were missing. Local leadership worked around the clock to account for every patient and teammate and to arrange transportation for urgent access to the dialysis care that many patients required to stay alive. Our Asheville Kidney Center opened on the Sunday right after Hurricane Helene, running on generated power to deliver care for patients from six nearby facilities. We, along with others in the kidney care community, opened our doors to anyone who needed treatment, including people who normally receive care from other providers. It made me proud to watch the dialysis community unite in shared support of patient care. Together with the commitment of our local care teams, our effective emergency response has once again highlighted how important scaled resources and operating discipline are. Even though the storms have passed, we're still working to coordinate humanitarian needs, such as food, housing, and other assistance; we continue to partner with the affected communities as they rebuild. My thanks to all the teammates who have gone above and beyond to look after each other and our patients. Beyond the impact on the community, Hurricane Helene disrupted key supply lines when Baxter's North Cove facility closed. Baxter provides us with the majority of our peritoneal dialysis, or PD, solution used for home PD therapy, along with the majority of our saline used during each in-center hemodialysis treatment. Baxter and other manufacturers have managed to supply enough for all our current PD patients to keep receiving treatment with relatively little interruption. So even though we've had to put a temporary hold on bringing new patients into PD, that's thanks to the tremendous work done by our regulators, government officials and Baxter. We're looking to restart new PD starts next month, and we anticipate supply dynamics will get back to normal in the first quarter. Moving on to sailing, Baxter can currently provide us with roughly 60% of what they were supplying before the storm, and they're still working to get the North Cove facility operational again. Luckily, we managed to line up alternative supply so that care continues uninterrupted and our patients stay safe. Since these problems cropped up close to the end of the quarter, there was only a minimal effect on Q3 financial results. When it comes to the fourth quarter, we're projecting a hit of somewhere around $10 million to $20 million, driven by elevated supply costs, fewer new PD patients and reduced productivity among our home caregivers. That figure is now baked into our 2024 adjusted operating income guidance range, and we anticipate that a portion of this quarterly impact will carry over into 2025, depending on how long the supply challenges last. Let me now move to what we expect from the CMS ESRD final rule, which should be published before long. There are numerous elements to the rule, but our main focus will be on two areas. The first is the market basket update, which includes the way CMS deals with the newly proposed wage index and the base rate. As you'll recall, the proposed rule resulted in an increase of about 2.1%. The second involves oral-only drugs moving into the bundle starting January 1. As you'll recall, this is a statutory mandate under which oral-only drugs — primarily phosphate binders — will shift from the Medicare drug benefit over to Medicare Part B. CMS has made it clear it wants these drugs in the bundle, but we're still waiting on details like initial reimbursement and how unbillable items will be treated; we remain of the belief that moving these therapies into the bundle will give more patients access to them; we understand that certain pharmaceutical manufacturers are still pushing for legislation that would postpone implementation of this rule that has existed for a long time, but we urge legislators to prioritize patient access. We stand ready to carry out this transition for the benefit of our patients. Moving to our third quarter performance, adjusted operating income came in at $535 million and adjusted earnings per share was $2.59. We see our third quarter results as pretty straightforward, in line with how we've generated value across this whole year. Even though growing treatment volume is still difficult, our business keeps showing resilience as we counter the volume headwinds through margin expansion, including momentum from our IKC and International results, all while we keep investing in our future. Cash flow is still robust and we keep executing our disciplined capital allocation strategy, giving capital back to shareholders via share repurchases. Now for the full year. We're still on track to produce results in line with our 2024 guidance range. We're reaffirming our 2024 adjusted operating income guidance of $1.91 billion to $2.01 billion. The impact from the Baxter supply shortage is now part of this forecast. Providing specific guidance for 2025 is a little premature, even though I realize a lot of you are already focused on next year. During the coming months, we'll gain further clarity on several key items, among them open enrollment, oral drugs in the bundle, and integrated kidney care, plus others; accordingly, formal 2025 guidance will come on the fourth quarter call, in line with how we normally do things. With that said, some multiyear perspective could be useful. Following difficult years in 2021 and 2022 amid the pandemic, we are now positioned to achieve a second straight year of double-digit adjusted OI growth, even as volume and labor pressures persist. Going ahead, we anticipate a return to adjusted OI growth that aligns more closely with the historic multi-year pre-pandemic guidance we've given. I'll hand things over now to Joel, who will cover our financial performance and outlook in greater detail.
Joel Ackerman
executiveThank you, Javier. Turning to the quarter, adjusted operating income came in at $535 million, adjusted EPS landed at $2.59, and free cash flow reached $555 million. Let me walk through a few specifics underlying the Q3 results. On a quarter-over-quarter basis, treatment volume per day held steady. That matched what we had anticipated, reflecting sustained strong admissions that were offset by elevated mortality along with somewhat higher mistreatment rates stemming from severe weather — specifically Hurricane Beryl in July and Hurricane Helene in September. We continue to feel confident that treatment volume growth for the full year will land in the 0.5% to 1% range. Revenue per treatment rose by more than $4 compared with the second quarter, which was consistent with our expectations. Our revenue cycle performance is upholding the strong RPT results we've delivered all year; we continue to anticipate full-year RPT growth within the 3.5% to 4% range. Patient care cost per treatment rose $2 on a sequential basis. That largely stemmed from persistent labor cost pressure as well as greater medical benefits expense during the quarter. G&A costs rose by $19 million quarter-over-quarter, driven by the usual quarterly unevenness in the timing of expenses. Depreciation and amortization climbed by $11 million in Q3 relative to Q2, owing to higher center closure costs. International OI edged up in the quarter, reflecting strong operational performance that was offset by $4 million of unfavorable foreign exchange impact. Adjusted operating results in Integrated Kidney Care, our value-based care segment, rose $32 million sequentially, thanks to lower costs in our special needs plans and the timing of revenue recognition tied to CKCC, the government value-based care demonstration program. As we always do, we recommend assessing IKC performance annually, given how prone it is to quarterly swings. We continue to believe IKC will post a full-year operating loss of roughly $50 million. Below the OI line, third quarter debt expense came in $37 million above Q2; two main factors drove this. First, our 2% interest rate caps expired at the end of June, and the caps we have now carry a weighted average rate of about 4.3% for the remainder of 2024; this effect aligns with our expectations and matches the guidance we gave at the start of the year. The second factor behind this quarter's increase was the additional debt we raised in August. After our second-quarter earnings call, we successfully closed two debt transactions totaling $2.1 billion. We used the proceeds from these deals in part to repay our Term Loan B maturing in 2026, which means our nearest debt maturity is now 2028. Leverage at the end of Q3 stood at 3.17 times EBITDA, a modest rise from Q2, while still sitting below the midpoint of our target range of 3 times to 3.5 times EBITDA. During the third quarter, we repurchased 2.7 million shares, and we have repurchased roughly 600,000 shares so far in October. Let me wrap up with a few remarks on what's left of 2024 and our thinking as we head toward 2025. Like Javier mentioned, we're restating our guidance for adjusted OI at $1.91 billion to $2.01 billion. Even with the hurricane-related OI hit we anticipate in Q4, we believe ongoing operating momentum will more than cover that headwind; we're also keeping our adjusted EPS outlook at $9.25 to $10.05, along with free cash flow of $950 million to $1.2 billion. Turning to 2025, as Javier noted, providing formal guidance now would be premature. On certain earnings components, I want to highlight several unusual possible headwinds and tailwinds that fall outside typical dynamics. On the headwind side: first, mortality is expected to stay elevated during 2025. Second, we anticipate the effects from the Baxter facility closure carrying into 2025. Third, the entire year's impact from our 2% interest rate caps expiring will drag EPS lower. On the tailwind side: first, center closure costs declining in 2025, which we flagged last quarter. Second, a favorable OI effect from our international segment, fueled by the Latin America acquisitions. And last, we'd see including orals in the bundle as a tailwind should pharma companies fail to secure legislation postponing that inclusion. Finally, on RPT and PCC growth, we anticipate both will be elevated compared with pre-COVID levels. We'll provide an update on each of these items plus more quantitative guidance during the Q4 earnings call. That wraps up my prepared remarks today. Operator, please open the call for Q&A.
Andrew Mok
analystHello, and good afternoon. From what I gathered, quite a few operational adjustments were made to deal with the hurricanes, though the bulk of those effects would show up in Q4. So I was hoping to get a clearer picture on two things: first, to what extent did the hurricanes affect 3Q treatment volumes, if at all? And second, Joel, I believe you repeated that treatment growth for the full year would land somewhere between 50 basis points and 100 basis points, which suggests a pretty meaningful pickup in 4Q even though hurricanes likely hit harder then; so I just want to grasp how to reason about that and reconcile those remarks. Thanks.
Joel Ackerman
executiveYes, thank you, Andrew. Regarding Q3, I would point to roughly 10 basis points of hurricane impact, and that appears within the mistreatment rate; as for Q4, my sense is this does not really alter the way we viewed Q4 prior to the hurricanes.
Andrew Mok
analystTurning to Q4, should we assume the hurricanes won't affect volumes in that quarter?
Joel Ackerman
executiveTo a lesser degree — much lower than the 10 basis points we've observed up to now. Clearly, we're not through the quarter yet, so more difficulties could arise. Even so, as things stand, no, it should come in under 10 basis points.
Andrew Mok
analystUnderstood. Alright, and I appreciate the early remarks regarding 2025's tailwinds and headwinds. Could you assist us in grasping the magnitude of a few of those? And I'm particularly hoping you might address what financial effect the addition of phosphate binders could potentially have on results for next year. Thank you.
Javier Rodriguez
executiveSure, I'll address the phosphate binders part last, actually, since we made a real effort to provide a meaningful range; regrettably, that's not possible, simply because insufficient data exists to produce a meaningful figure. So allow me instead to walk through the mechanics underneath, so that everyone shares the same understanding. To begin with, phosphate binders represent a category of medications that will constitute the largest portion of the orals within the bundle. The initial issue is that we lack knowledge, since the rule has not yet been issued, though we anticipate learning soon what reimbursement the government will set. Second, four products make up the phosphate binders, and the proportion among them remains unknown to us. Pricing varies considerably across those four, depending on whether they're branded or generic. On top of that, the branded ones have faced restrictions and authorizations and similar requirements, and once those disappear, we can't predict how the mix will shift. Finally, there's the matter of volume. Roughly 10% to 15% of our patients lack Medicare Part D and were not taking part in these orals in the bundle, which is precisely why we view this as such a positive development for access among those patients. Consequently, we don't know how that volume will behave; so once you begin manipulating these variables, the possibilities become rather broad, because fundamentally volume might shrink, while reimbursement spans a wide range. And the factor that truly injects a great deal of variability is pricing along with the mix within that pricing. So sadly, we'll need to wait until next quarter before offering you a stronger figure and a clearer picture of it.
Joel Ackerman
executiveCorrect. Andrew, regarding the initial portion of what you asked — I listed five elements: three that help and two that hurt, all affecting operating income. Interest expense was another one, though it impacts only EPS. Similar to the orals in the bundle, it's difficult, since many fluctuating variables might come into play for every one of them. Therefore, I won't put individual figures on them. Having said that, when building a model, a sensible place to begin would be assuming the positive and negative forces balance out at the OI line.
Andrew Mok
analystUnderstood. So regarding that target growth figure you mentioned, the one I believe sits at 3% to 7% from before COVID, does that already account for every one of those headwinds and tailwinds? Is that the correct way to look at it?
Joel Ackerman
executiveYes, I'd say so — that sounds right to me.
Andrew Mok
analystGreat. Thanks for the color.
AJ Rice
analystThanks. Hi, everybody. I believe I already know what the answer is on this clarification, but I want to confirm it for the record. That $10 million to $20 million of hurricane impact — my assumption is that figure is EBITDA rather than revenue. And then perhaps more generally regarding treatment patterns. I recall you mentioning last quarter that new to therapy had returned to pre-pandemic levels; it sounds like it was positive once more this quarter. I just want to — is there any — is it stronger or is it about the same? Also, when you mention those higher mistreatment figures, does that come only from the hurricane, or are other factors at play? Then, regarding mortality, it sounds like you're now pushing that into 2025. Is that simply because this is your first time addressing '25? Or has something new emerged that's leading you to flag '25 when it comes to mortality — elevated mortality rates?
Joel Ackerman
executiveYes. Let me try to take these one at a time; so first, as far as Baxter's effect in Q4 goes, it would mostly show up in EBITDA. If we were to lose some patients to a competing provider that offers peritoneal dialysis, and those patients decided for whatever reason to switch, there could be a slight impact on the revenue line. That said, my sense is that the great majority of it won't show up as revenue. As for the three factors that drive volume, there's nothing new to report on admits; the trend is in line with what we've described previously. On the mistreatment rate — it's never simply storms, is it? Over the years, it has typically landed at roughly 6% on average across the year, though it doesn't hold steady from one quarter to the next; Q1 and Q4 usually run higher, while Q2 and Q3 are lower. Regarding the storms, those 10 bps were roughly 10 bps above what we'd likely have anticipated otherwise. That said, it doesn't represent the entire mistreatment rate. Turning to mortality, nothing fresh here seems to hurt how we see 2025. The ongoing elevated mortality that hasn't returned to pre-COVD levels—each quarter this persists, it shapes our thinking somewhat. Still, nothing emerged this quarter that materially shifted our outlook for next year.
AJ Rice
analystAll right, many thanks.
Pito Chickering
analystHello, good afternoon. Returning to that figure for growth in treatments that weren't acquired — clearly, plenty of attention is on it. Could you put a number on how many fresh patients came in during Q1, Q2, and Q3? Any details about how many were lost because of transplants during this year? Any insight into those individuals shifting toward different facilities or regions? I'm simply seeking any additional causes apart from death, since I'm attempting to reconcile the treatment growth they report, which they're showing alongside delayed USRDS quarterly figures on incidence and prevalence. Thanks.
Javier Rodriguez
executiveThanks, Pito. Let me address it broadly, since there's a bit of, shall we say, a restless energy around trying to determine what's going on with volume. Yet the truth is it's simply a matter of higher mortality; whenever you examine admit growth, it's solid. Whenever you examine the mix, it's solid. Whenever you examine transplants, they remain steady. It shifts slightly, yet it truly doesn't change the needle whatsoever. It fluctuates a bit. Our proportion of transplants has stayed steady. Thus ultimately, mistreatments might shift slightly in various places owing to storms or other seasonal factors, yet the majority of it stems from higher mortality.
Joel Ackerman
executiveYeah — and I’ll just…
Pito Chickering
analystMy apologies, please continue.
Joel Ackerman
executiveI’ll jump in briefly on the first item, which concerned NAG for the quarter, and I’ll share a bit of context on it. NAG on a quarterly basis can be volatile. If what you’re attempting is what I believe you’re attempting, namely teasing apart the volume trends all of us are trying to work out, then in my view quarter-over-quarter NAG isn’t a particularly good figure for that purpose. Embedded in that figure are things such as this treatment rate, and a great deal related to the timing of census across the quarter; so it’s down 60 bps quarter over quarter. I don’t believe that indicates anything material regarding where volume in general is heading.
Pito Chickering
analystAll right, that's reasonable. Here's a follow-up question about IKC. Your payer true-ups typically happen in Q3. This quarter, pairs experienced quite a bit of — how should we put it — somewhat choppy conditions. I'm just wondering how the 2023 payer true-up played out during Q3.
Joel Ackerman
executiveYeah. So for the year, we remain on track. As we've always done, I'd urge you and everybody else to evaluate IKC annually, not quarter by quarter. Our figure for the year, negative $50 million, is being reaffirmed — that's been the number throughout the year. And regarding the turbulence we've been reading about in the payer market, by and large it hasn't affected us.
Pito Chickering
analystAll right. But don't you typically handle those large yearly true-ups from the prior year in Q3?
Joel Ackerman
executiveIs that the— Joel Ackerman: Those happen in both Q3 and Q4, and everything is proceeding according to plan.
Pito Chickering
analystAll right. All right, that's reasonable. All right; now for the final question. Just examining commercial and MA price hikes for '25, or whether they need to track consistent with prior norms. Thanks a lot.
Javier Rodriguez
executiveYeah, there isn't anything noteworthy to mention. It's proceeding as anticipated.
Pito Chickering
analystGreat, thank you.
Javier Rodriguez
executiveThank you.
Lisa Clive
analystHello. Regarding the increase in volume, considering the ongoing decrease, what's the way we should view volume growth across this year? As I recall, you had been at 0.5% to 1%. Plus any perspective on 2025; and additionally, within IKC, might you provide any signal about how reimbursement is divided among capitated shared savings? That would be useful. Thank you.
Joel Ackerman
executiveSure, beginning with volume, for 2024, we continue to expect 50 bps to 100 bps of growth. Thus nothing has changed on that. About the IKC matter, I believe we will need to follow up with you later on that point. Was there a question I overlooked, Lisa?
Lisa Clive
analystNo, no. I was simply — right, I mean, I guess I'm just attempting to reason about how much IKC could expand, in terms of both the top line and revenue — it would help at some point to receive some sense of how the economics function in there. Thanks. But I'll hold off until you return to that.
Joel Ackerman
executiveGreat. Thank you.
Joanna Gajuk
analystHello, and many thanks for fielding my question. I suppose I'm simply building on the previous question regarding volumes, correct? So you still anticipate a slight increase across the year? And then, how ought we to consider, I suppose, the coming year and your sort of eventual objective of achieving 2% growth in same-store volumes?
Joel Ackerman
executiveYeah; so regarding the coming year, as Javier said, it's fairly — the bulk of the narrative concerns mortality and whatever occurs with mortality in the coming year. To add a bit more detail on that, I'd say, if you look at the midpoint of our range for this year of 75 basis points of growth, if you wish to consider how to model the coming year, there's a modest headwind on treatment days for the coming year, roughly 25 basis points. And then there's a single headwind plus a single tailwind. The headwind would relate to clinic closures. We highlighted that during the prior quarter as a source of headwind on volume for the year. And as the clinic closures recede further into the background, further into our history, then I believe we'll witness a modest tailwind from that. And then we might also possibly face a headwind in the coming year tied to PD and the Baxter issue that we're experiencing, and that's fairly straightforward. There are some patients who may wish to begin PD now. We lack the capacity to begin all of the new PD patients over the quarter, and they may go to a different provider. I'd describe those two items, the clinic closures and the Baxter PD, as offsetting. So you truly have the coming year, beginning with a base of this year's 75 basis points, minus 25 basis points of day mix; and so you begin with a base of 50 basis points. And then returning to what Javier said, it's for everyone to determine what they believe will occur with mortality in the coming year compared with this year. And then clearly mistreatment rate may also be another source of variability from one year to the next. So that's the framework I'd set out for how to consider it.
Joanna Gajuk
analystAlright. That's quite useful. I appreciate you addressing how the day's events affected things. If I could, though — there's one more thing I want to ask, but first let me pick up on the PD patients. So I suppose the question is, what does your home dialysis mix look like? And within that, how does PD break down against HD home?
Javier Rodriguez
executiveOur PD mix is unchanged, since this occurred at the close of the quarter, and it sits in the mid 15 range. HHD accounts for roughly a 2% mix. Let me use this opportunity to express gratitude to Baxter and the government. They have been incredible, putting in work literally all hours to ensure every one of our patients receives their supply; and so, based on what they've communicated to us, we'll clearly experience some modest deterioration in that during the fourth quarter, though we will return to normal by the first quarter and work to get all our patients back on track.
Joel Ackerman
executiveRight. And Joanna, one more point I want to make — with regard to those PD patients, keep in mind that we anticipate retaining the great majority of them. As for the new patients, a large portion of them — roughly 50% — are already receiving dialysis at our clinics, and we believe waiting a short while before switching to PD won't prove too burdensome for them. For those just starting dialysis who will ultimately go on PD, several paths exist: if they still have residual renal function, they might delay dialysis altogether, or they could begin treatment in-center and later make the move to PD. Beyond that, some may choose not to wait at all and instead seek care from a different provider. So the pattern we'd anticipate you noticing is a drop — possibly a sizable one — in our home mix during the coming quarter, though as for how many patients truly depart DaVita or never come aboard, our expectation is that figure won't be especially large.
Joanna Gajuk
analystAll right. That's really useful. If I can, I had one more question about the outlook for next year. I suppose this builds on what you said regarding RPT growth remaining elevated next year. So would you say you're suggesting that 3% to — 3.5% to 4%, which is what you're guiding toward this year, is the figure we should have in mind for next year, or is it somewhat lower, somewhat higher? How should we think about that? Thank you.
Joel Ackerman
executiveGuiding quantitatively at this point is premature, though my inclination would be that it's below that.
Joanna Gajuk
analystAlright, that's a bit under 3.5% to 4%, but what you're indicating is that it's above, say, the range you've seen historically?
Joel Ackerman
executiveThat's right.
Joanna Gajuk
analystOkay, that's great. Thanks a lot for taking my question.
Javier Rodriguez
executiveHey, Joanna, it's Javier here. Let me clear up what I said, since I don't believe I was as clear as I ought to have been. Home patients make up 15.5% of our mix overall, and within that, HHD accounts for 2%, while PD represents 13%. I don't think that was right.
Joanna Gajuk
analystAlright, so the percentage for PD is 13%. Got it, that's clear.
Javier Rodriguez
executiveThanks a lot. Appreciate it.
Ryan Langston
analystHello, and thanks. In the release, I believe it mentioned that advocacy costs for 3Q went up. Yet I think during the second quarter, they had declined compared with a year earlier. Could you give us some idea what those expenses tie back to?
Javier Rodriguez
executiveThere are a number of items happening with advocacy costs, though a few of the primary causes are California and its elections. Then, naturally, there's our work involving restoring patients in Washington, D.C. Finally, the last item would be orals in the bundle, since you may have heard about certain campaigns by pharmaceutical companies attempting to push back orals in the bundle; as a result, we must marshal our resources in Washington, D.C. so that people understand the benefits orals in the bundle can provide.
Ryan Langston
analystUnderstood. Then one final item from me. Regarding mistreatment, this marks a second straight quarter where it's been higher, and that's due to weather. If we assume no further hurricanes or similar weather occurrences and so on, should we anticipate a return to roughly the typical historical norms? Thank you.
Joel Ackerman
executiveThe mistreatment rate remains above what it was before COVID. So absent any more storms, our expectation is that it will keep declining gradually. How quickly that happens isn't yet clear. With that said, keep in mind there's a seasonal increase during Q4. Therefore, even if no further storms occur, you'd anticipate the mistreatment rate rising in Q4.
Ryan Langston
analystUnderstood. Grateful for the assistance. Thanks.
Joel Ackerman
executiveThanks.
Justin Lake
analystThank you. Evening, everyone. To start off, I want to return to what you said about headwinds and tailwinds. I didn't catch any reference to RPT annualizing, or how the strength of 2024 carries into next year on an annualized basis. Based on my own figures, previously I had you moving from 2.5% to 3% to 3.5%, correct? That means your guidance went up by 1%. Much of that builds gradually during the back half of the year. So my expectation would have been that the annualization of that robust second-half '24 growth would serve as a fairly solid tailwind heading into 2025. Do you have any thoughts on this? Is there something I'm overlooking?
Joel Ackerman
executiveYes, Justin, your math checks out, and our comments still hold; as you can imagine, we had plenty of discussions about which items to label as unique headwinds and tailwinds as opposed to non-unique ones; so I believe our position stands, and that is the reason we noted that RPT will come in above normal next year. We simply decided against placing it within the category of headwinds and tailwinds that we identified.
Justin Lake
analystJustin, I'll follow up on that separately. Now, regarding the $135 million in interest expense — should we view that as a solid baseline, or might it drift upward as we move into 2025?
Joel Ackerman
executiveJoel, I'd say it's a solid baseline. In fact, our caps for the coming year come in a bit under what we have this year. So that should hold up. To clarify, that $135 million figure represents the increase for next year. So you ought to frame it as $270 million across the year. Oh, wait a moment — my team is signaling me. Justin, give me a second and I'll circle back.
Justin Lake
analystYeah, yeah. Just so we're clear, my point wasn't about the year-over-year comparison. I was only referring to the —
Joel Ackerman
executiveMy apologies — the $135 million for the quarter, that's a fairly solid figure; when it comes to next year, as a quarterly figure it might decline, since our caps are somewhat lower. But if you consider the two factors pushing that number higher, it's additional debt, and I wouldn't anticipate us taking on more debt across the coming few quarters, and beyond that our caps won't shift in any meaningful way.
Justin Lake
analystAll right. So do those caps have an expiration date, or are they sort of priced at a sensible level? Meaning, you could renew them today, correct? If they ran out at the close of next year and rates stayed the same, you'd be okay.
Joel Ackerman
executiveRight; we've altered our approach to this. There's roughly a — there's a cliff — at the finish of Q2 we had one, since previously we'd go with a cap lasting three years or four years; these days it's done on a rolling basis. As a result, moving forward you wouldn't witness a dramatic shift of this kind. It'll step up and down steadily based on where rates stand at the moment those caps get set.
Justin Lake
analystGreat. And finally, sorry if this got past me, but for the quarter did you provide a mix figure compared with the commercial mix of 11% you mentioned during the prior quarter?
Joel Ackerman
executiveYeah, for any of our typical mix figures, there truly were no significant changes in the mix.
Justin Lake
analystGreat, thank you.
Andrew Mok
analystHi, thanks. Thanks for letting me back in. I just wanted to follow up on G&A. It looks like that was up 7% sequentially and 10% year over year. What were the drivers of that in the quarter?
Javier Rodriguez
executiveYes, in G&A, we have a lot going on because we're trying to really go through the entire continuum of care and unite it, all the transitions of care. But the big bulk of it is going into IT is going in. Then, naturally, part two involves labor costs, while part three covers what we spent on reimbursement operations, which drove the gain in revenue per treatment. Together, those factors account for nearly all of the uptick.
Andrew Mok
analystUnderstood. Alright. Then perhaps as a follow-up regarding the commercial mix: within that commercial mix, what portion is made up of the ACA exchange mix, within that 11%? And what level of growth are you observing on the ACA exchanges during this year? Thanks.
Javier Rodriguez
executiveSo, simply to ensure I'm using the correct terminology, I believe we're talking about the QHPs. So, when it comes to the QHPs, the nation is at roughly a 7% to 8% mix, while our population sits at about a 3% mix. Consequently, we are underrepresented, since with QHPs, should one of our patients choose Medicare, they exit the QHP. That is the reason we are underrepresented.
Andrew Mok
analystUnderstood. Could you help us understand what level of expansion you've recorded among that payer category? Thank you.
Javier Rodriguez
executiveOur growth matches the market's pace precisely. In other words, those two lines have sat directly atop one another.
Andrew Mok
analystAlright, I appreciate all the detail you provided.
Javier Rodriguez
executiveYou're welcome.
Pito Chickering
analystHi, everyone. Just a brief additional question regarding 2025. Is depreciation going to serve as an additional benefit in the coming year?
Joel Ackerman
executiveMy apologies, I couldn't catch that. Pito, would you mind repeating it?
Pito Chickering
analystYes, you bet. Will depreciation be another tailwind for next year EPS?
Joel Ackerman
executiveIt'll be flat to down. Well, the answer is yes. Part of it comes from the center closure number coming down, but excluding that, it'll be flat to down.
Pito Chickering
analystAll right. So if I just run a few rough calculations in my head, I understand the mortality piece — without a PD, that's a negative. But Baxter is bringing their facilities online quite quickly. So that's largely taken care of in the first — portion of the first quarter. The things Justin asked about, interest rate caps, that's simply arithmetic. With center closures, international, again that's just arithmetic. Wherever the bundle lands, once you combine the headwinds and tailwinds, depending on the bundle, could it actually turn out that this is more of a tailwind than a headwind? But we simply want to see where the bundle ends up. Is that a reasonable way to think about it?
Joel Ackerman
executiveI'm — Just help me once more with the end of the question, Pito. What exactly are you asking about whether it's a headwind or tailwind? The bundle?
Pito Chickering
analystYeah, so the favorable factors appear — if I just add up the numbers regarding the unfavorable factors, I follow those and I follow how the favorable factors calculate out. The largest unknown in this case appears to involve the bundles. And so based on...
Joel Ackerman
executiveUnderstood. All right.
Pito Chickering
analystWhere the bundle ultimately lands will determine if we're dealing with something helping us or hurting us — versus, perhaps, what you described as a push. Should the pricing we receive arrive shortly, my guess is that could lean more favorable, contingent on what the government announces within 1 or 2 weeks. Does that strike you as a reasonable frame?
Joel Ackerman
executiveMy sense is that several of these lines carry somewhat greater swing than you seem to be allowing for. Take orals — they might improve, they might decline. Still, each of them likely offers a fair bit of room to move; so in my view it could break either direction, ending up either a net headwind or a net tailwind.
Pito Chickering
analystAll right, that's reasonable. Thanks, everyone.
Javier Rodriguez
executiveAll right, thanks, Michelle. And thanks to all of you for the interest you've shown in DaVita. We'll close out this call the same way we began it, by expressing gratitude for the dedication shown by our DaVita Care teams on our patients' behalf. Even though recent storms will bring some extra costs, we except to — we expect those expenses to be absorbed by the ongoing strong results of our underlying business. We've discussed volume extensively, and as we noted, though mortality is still elevated, the money we've put into people, infrastructure, and capabilities has brought our operating income back to the pre-pandemic trajectory. We appreciate your continued interest, and be well.
Operator
operatorThank you. This concludes today's conference call. You may go ahead…
Read the full transcript via the API
You're viewing the first half of this call. Get the complete DaVita Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to DaVita Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in DaVita Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.